Moderna and Merck announced positive five-year follow-up data from the Phase 2b study of intismeran autogene (mRNA-4157). This investigational personalized cancer vaccine was tested in combination with Merck's Keytruda.
The combination therapy demonstrated sustained, clinically significant improvement in recurrence-free survival. This outcome applies to patients with high-risk stage III/IV melanoma following complete surgical removal.
The combination treatment reduced the risk of cancer recurrence or death by 49%. This result compares the combination to Keytruda used alone.
The five-year data remains consistent with previous three-year results. This outcome marks a significant milestone for Moderna's mRNA platform in oncology.
Moderna seeks to expand its pipeline beyond infectious disease vaccines. The companies are advancing the therapy into Phase 3 trials across multiple cancer types.